The Wall Street Journal94d agoneutral
When Diets Don’t Work: Parents Turn to Wegovy for Elementary School KidsDoctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
149last 24h
875last 7d
144● bullish (7d)
96● bearish (7d)
214publishers
Motley Fool96d agoneutral
Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.
Bloomberg99d agoneutralVIDEO
J&J Has No Plans to Enter Obesity Drugs Market, CEO SaysJohnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.
Bloomberg99d agoneutral
Snubbing Nvidia for Adobe Costs Florida Stock-Picker $50 Billion(Bloomberg) -- It was 180 degrees off the hot trade on Wall Street. Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingIran’s Deputy Foreign Minister Confirms Deal Reached With USNetanyahu Pays a Political Price for Trump’s Iran DealUS Set to Offer Iran Broad Financial Gains in Peace DealSnub Nvidia Corp., the soaring king of artificial intelligence chips. Embrace Adobe Inc., a sinking casualty of AI disruptio
Reuters Videos99d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
TheStreet100d agoneutral
Eli Lilly’s hottest drugs face a quiet new threatEli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
The Wall Street Journal100d agoneutral
Health Care Roundup: Market TalkGain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.
MT Newswires100d agoneutral
European Stocks Higher in Tuesday Trading; Markets Buoyed by US, Iran Peace Deal; Inflation Remains a ConcernThe European stock markets were modestly higher in Tuesday trading as the markets reacted positively
Investor's Business Daily101d agoneutral
This Financial Bellwether Bankrolls A BreakoutLed by top holdings like Popular, East West Bancorp and Zions, KRE ETF is in buy range as the financial ETF flashes signs of strength.
Reuters101d agoneutral
India's Electronics Mart eyes new markets as tech hubs fear job lossesHyderabad-based Electronics Mart India is looking to diversify away from the technology hub as concerns grow that potential AI-triggered job losses could hurt consumer spending, a top executive said. The retailer gets about 60% of its revenue from Hyderabad, which hosts offices of global companies such as JPMorgan Chase and Eli Lilly, and Indian IT majors Wipro and Infosys. Around a fifth of its stores in Hyderabad are located in neighbourhoods where the majority of the residents are software employees.
Investor's Business Daily104d agobullish
Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.With the massive SpaceX debut hogging the headlines, some retail investors may have allowed more prosaic names to slip from their minds. Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. Eli Lilly is committed to innovation and reinvests 20%-25% of its sales back into developing new treatments.
Investing.com105d agoneutral
SpaceX’s historic IPO catapults it past some of America’s biggest namesInvesting.com -- Elon Musk’s SpaceX on Thursday said that it has priced its initial public offering at $135 per share on Thursday, raising $75 billion in the largest IPO in U.S. history.
Reuters106d agobullish
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagonBy Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to
Investor's Business Daily107d agobearish
Dow Jones AI Giant Nvidia Stock Tumbles To Key Support Level Amid Market Sell-OffDow Jones AI giant Nvidia stock tumbled to a key support level during Tuesday's stock market sell-off. A decisive bounce would be bullish.
BioPharma Dive107d agoneutral
Stealthy startup Treeline plans a reverse mergerLed by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
Bloomberg107d agoneutral
Pentagon Accuses Alibaba, Baidu of Aiding China’s Military(Bloomberg) -- The Pentagon accused some of China’s biggest companies, including Alibaba Group Holding Ltd., Baidu Inc. and BYD Co. of supporting the Chinese military, doubling down on an earlier decision to label crown jewels of the country’s corporate world as threats to US national security.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump Says He, Not Congress, Is in Charge of Kennedy Center
Motley Fool108d agoneutral
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?Infectious disease could fuel Eli Lilly's next growth phase.
Bloomberg108d agobullishVIDEO
Campbell's Earnings Beat; Eli Lilly Obesity Drug Results | Stock MoversOn this episode of Stock Movers with Alexis Christoforous: - Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate. - Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company's incretin portfolio is "not built around singular blockbusters." - Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell's in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement.
Investor's Business Daily108d agobullish
Big Pharma Stock Eli Lilly Concocts New Buy ZonePopping onto the IBD Leaderboard and two exclusive screens, Eli Lilly stock has returned to buy range after a brief hiccup.
The Wall Street Journal108d agoneutral
Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial SuccessA late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.
The Wall Street Journal109d agoneutral
Your Weight-Loss Drugs Are Next on the Corporate Chopping BlockMore employers are requiring weigh-ins, app tracking and health coaching before approving GLP-1s for losing weight—or dropping coverage altogether.
TheStreet110d agoneutral
Eli Lilly makes surprising retreat from major marketEli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June 3, 2026. The pullback lands ...
Investor's Business Daily112d agobearish
Dow Jones Hits High, AI Stocks Shrug Off Broadcom, Ciena Sell-Offs; Jobs Report LoomsDow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.
Investor's Business Daily112d agobullish
Eli Lilly, IBD Stock Of The Day, Flashes Two Buy SignalsEli Lilly stock is Thursday's IBD Stock Of The Day as the weight-loss behemoth deepens its focus on gene editing, vaccines and cancer.
The Wall Street Journal113d agoneutral
Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment DealEli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
TheStreet115d agoneutral
Eli Lilly scores a first in major pharma milestoneEli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio. That’s a clean sweep ...
Investing.com116d agoneutral
Could GLP-1 drugs become oncology’s next big opportunity?Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.